Healthy Vaccinee Bias and MenB-FHbp Vaccine Effectiveness Against Gonorrhea.

Autor:	Abara WE; From the Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA., Bernstein KT; From the Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA., Lewis FMT, Pathela P; Bureaus of STI., Islam A; Philadelphia Department of Public Health, Philadelphia, PA., Eberhart M; Philadelphia Department of Public Health, Philadelphia, PA., Cheng I; Immunization, New York City Department of Health and Mental Hygiene, New York City, NY., Ternier A; Immunization, New York City Department of Health and Mental Hygiene, New York City, NY., Sanderson Slutsker J; Bureaus of STI., Madera R; Philadelphia Department of Public Health, Philadelphia, PA., Kirkcaldy R; From the Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
Jazyk:	angličtina
Zdroj:	Sexually transmitted diseases [Sex Transm Dis] 2023 Jun 01; Vol. 50 (6), pp. e8-e10. Date of Electronic Publication: 2023 Mar 02.
DOI:	10.1097/OLQ.0000000000001793
Abstrakt:	Abstract: Observational studies demonstrated 30% to 40% effectiveness of outer-membrane vesicle (OMV) meningococcal serogroup B vaccines against gonorrhea. To explore whether healthy vaccinee bias influenced such findings, we examined the effectiveness of MenB-FHbp, a non-OMV vaccine that is not protective against gonorrhea. MenB-FHbp was ineffective against gonorrhea. Healthy vaccinee bias likely did not confound earlier studies of OMV vaccines. Competing Interests: Conflict of Interest and Sources of Funding: None declared. (Copyright © 2023 American Sexually Transmitted Diseases Association. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu